A de novo expression of CTLA-4 was induced in 71.4% (5/7) and 85.7% (6/7) vs. 42.8% (3/7) IC-negative melanoma cells, treated with guadecitabine and DAC vs. AZA, respectively, with mean values ± SD of CTLA-4 molecules 1.16E-03 ± 1.73E-03 and 1.44E-03 ± 2.49E-03 vs. 2.31E-04 ± 1.07E-04, respectively (Figure 3A). Here, CTLA4 is linked to melanoma.